RCS - GenIP PLC - New Report Orders From Repeat Clients

GenipAnnouncement

21/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251121:nRSU4234Ia&default-theme=true

RNS Number : 4234I  GenIP PLC  21 November 2025

 

 

 

21 November 2025

 

GenIP Plc

("GenIP" or the "Company")

 

New Report Orders From Repeat Clients

 

 

GenIP Plc, an AI-powered innovation intelligence and technology
commercialisation company, is pleased to announce it has received a total of
57 new report orders from repeat clients, including two leading U.S. research
universities and a returning UK institution. These orders reflect continued
demand for GenIP's AI-enabled analytical products and the strengthening of
long-term client relationships.

 

The Company has secured 50 new Invention Evaluator report orders from two
major U.S universities, both recognised for their substantial innovation
output and commercialisation performance: One institution has been repeatedly
ranked in the National Academy of Inventors "Top 100 U.S. Universities Granted
Utility Patents", demonstrating sustained leadership in translating research
into protected intellectual property. The other operates one of the most
active university innovation hubs in the United States, publicly tracking
thousands of invention disclosures, patent filings, and spinoff ventures
annually through its dedicated commercialisation centre.

 

In addition, a UK university first onboarded in June 2025 has placed a further
7 report orders, demonstrating continued engagement and the recurrent nature
of GenIP's services.

 

GenIP believes these repeat orders validate GenIP's value proposition and
demonstrate the effectiveness of our AI-powered analytical assessments in
supporting technology transfer decisions.

 

Melissa Cruz, CEO of GenIP, commented:

 

"The continued return of leading institutions reinforces the market's need for
faster, more reliable decision-support in technology commercialization. We are
also seeing a rise in inbound referrals from universities that have reported
meaningful improvements in their licensing workflows after adopting our
evaluations. This combination of repeat business and organic referrals gives
us strong confidence in our growth trajectory as we expand our AI-powered
product suite and support more clients globally."

 

 

For further information regarding GenIP, please visit www.genip.ai
(http://www.genip.ai/) , or contact:

 

 GenIP Plc                                  Via Redchurch Communications

 Melissa Cruz, CEO

 Redchurch Communications (Financial PR)    genip@weareredchurch.com (mailto:genip@weareredchurch.com)

 John Casey

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

 

Notes to Editors

 

About GenIP

 

GenIP is a next-generation consultancy at the intersection of generative AI
and innovation strategy. We empower corporates, venture funds, and research
institutions to evaluate, commercialise, and scale breakthrough technologies.
By combining proprietary GenAI algorithms with expert human analysis, GenIP
delivers decision-grade insights and talent solutions that accelerate
innovation outcomes.

 

Service Offerings

 

GenIP operates through two synergistic service lines:

 

 Service                               Description                                                                   Value Proposition
 Invention Intelligence Product Suite  AI-powered market intelligence reports assessing the commercial potential of  Enables faster, evidence-based decisions on R&D prioritisation,
                                       emerging technologies                                                         investment, and IP strategy
 Talent and Executive Search Services  Executive search platform using machine learning and NLP to match             De-risks scaling by aligning technical vision with proven executive capability
                                       innovation-driven organisations with commercialisation-ready leadership

 

Together, these services form a unified GenAI-enabled platform for innovation
triage and execution.

 

Vision & Strategy

 

GenIP aims to become the global leader in generative AI analytics for
innovation commercialisation. Our strategy is anchored in three growth
pillars:

 

●    Organic Expansion

Scale Invention Evaluator and Recruitment Services through targeted outreach
to corporates, VCs, and research institutions, supported by strategic
marketing and digital engagement.

●    Service Deepening

Enhance functionality and margin by expanding GenAI capabilities within both
service lines-unlocking new use cases and customer segments.

●    Strategic Acquisitions

Pursue bolt-on acquisitions of complementary GenAI services with validated
market traction to broaden our offering and accelerate growth.

 

-ENDS-

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPKKBNPBDDCDB



            Copyright 2019 Regulatory News Service, all rights reserved